Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease in Asturias. FOSFASTUR study

J. Emilio Sanchez-Alvarez,Elena Astudillo Cortés,Miguel Seras Mozas,Raúl García Castro,Carlos Miguel Hidalgo Ordoñez,Ana Cristina Andrade López,Catalina Ulloa Clavijo,Anna Gallardo Pérez,Carmen Rodríguez Suarez

NEFROLOGIA（2021）

引用 0|浏览3

暂无评分

摘要

Alterations in bone and mineral metabolism are very common in chronic kidney disease (CKD). The increase in phosphate levels leads to bone disease, risk of calcification and greater mortality, so any strategy aimed at reducing them should be welcomed. The latest drug incorporated into the therapeutic arsenal to treat hyperphosphataemia in CKD is Sucroferric Oxyhydroxide (SFO).

查看译文

关键词

Hyperphosphataemia,Phosphate binders,Sucroferric oxyhydroxide,Haemodialysis,Peritoneal dialysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要